These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 16504671)

  • 1. The weight of pharmacokinetic parameters for mycophenolic acid in prediction of rejection outcome: the receiver operating characteristic curve analysis.
    Pawinski T; Durlik M; Szlaska I; Urbanowicz A; Ostrowska J; Gralak B; Majchrzak J
    Transplant Proc; 2006; 38(1):86-9. PubMed ID: 16504671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
    Pawinski T; Durlik M; Szlaska I; Urbanowicz A; Majchrnak J; Gralak B
    J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mycophenolate pharmacokinetics in early period following lung or heart transplantation.
    Ensom MH; Partovi N; Decarie D; Ignaszewski AP; Fradet GJ; Levy RD
    Ann Pharmacother; 2003 Dec; 37(12):1761-7. PubMed ID: 14632536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients.
    Kuypers DR; Claes K; Evenepoel P; Maes B; Vanrenterghem Y
    Clin Pharmacol Ther; 2004 May; 75(5):434-47. PubMed ID: 15116056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inadequate mycophenolic acid exposure and acute rejection in kidney transplantation.
    Sánchez-Fructuoso AI; de la Higuera MA; Giorgi M; Ramos F; Garcia Ledesma P; Calvo N; Pérez-Flores I; Barrientos A
    Transplant Proc; 2009; 41(6):2104-5. PubMed ID: 19715844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time to reach tacrolimus maximum blood concentration,mean residence time, and acute renal allograft rejection: an open-label, prospective, pharmacokinetic study in adult recipients.
    Kuypers DR; Vanrenterghem Y
    Clin Ther; 2004 Nov; 26(11):1834-44. PubMed ID: 15639695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of an abbreviated pharmacokinetic profile for the estimation of mycophenolic acid exposure in pediatric renal transplant recipients.
    Weber LT; Hoecker B; Armstrong VW; Oellerich M; Tönshoff B
    Ther Drug Monit; 2006 Oct; 28(5):623-31. PubMed ID: 17038876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics in renal transplant recipients under treatment with cyclosporine and Myfortic.
    Brunet M; Crespo M; Millán O; Serón D; Torregrosa V; Jiménez O; Moreso F; Martorell J; Grinyo JM; Oppenheimer F
    Transplant Proc; 2007 Sep; 39(7):2160-2. PubMed ID: 17889124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of mycophenolic acid during the early period after renal transplant.
    Nazemian F; Mohammadpur AH; Abtahi B; Naghibi M
    Exp Clin Transplant; 2007 Dec; 5(2):658-63. PubMed ID: 18194117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood cyclosporine level soon after kidney transplantation is a major determinant of rejection: insights from the Mycophenolate Steroid-Sparing Trial.
    Gotti E; Perico N; Gaspari F; Cattaneo D; Lesti MD; Ruggenenti P; Segoloni G; Salvadori M; Rigotti P; Valente U; Donati D; Sandrini S; Federico S; Sparacino V; Mourad G; Bosmans JL; Dimitrov BD; Iordache BE; Remuzzi G
    Transplant Proc; 2005 Jun; 37(5):2037-40. PubMed ID: 15964332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic drug monitoring of mycophenolic acid in renal transplant recipients.
    Okamoto M; Wakabayashi Y; Higuchi A; Kadotani Y; Ogino S; Ushigome H; Akioka K; Kaihara S; Yoshimura N
    Transplant Proc; 2005 Mar; 37(2):859-60. PubMed ID: 15848556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of enteric-coated mycophenolate sodium: comparative study in patients with autoimmune disease and renal allograft.
    Neumann I; Fuhrmann H; Kanzler M; Fang IF; Jaeger A; Graf H; Bayer P; Kovarik J
    Expert Opin Pharmacother; 2008 Apr; 9(6):879-86. PubMed ID: 18377332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in Chinese kidney transplant recipients treated with mycophenolate mofetil.
    Lu YP; Lin B; Liang MZ; Wang L; Nan F; Yu Q; Tang KS
    Transplant Proc; 2004 Sep; 36(7):2079-81. PubMed ID: 15518752
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacokinetics of mycophenolic acid and its phenolic-glucuronide and ACYl glucuronide metabolites in stable thoracic transplant recipients.
    Ting LS; Partovi N; Levy RD; Riggs KW; Ensom MH
    Ther Drug Monit; 2008 Jun; 30(3):282-91. PubMed ID: 18520599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between pharmacokinetic parameters of cyclosporin and the incidence of acute rejection after heart transplantation.
    Aumente MD; Arizón JM; Segura J; López A; Albornoz R; Cárdenas M; Segura C
    Transplant Proc; 2005 Nov; 37(9):4014-7. PubMed ID: 16386613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a predictive limited sampling strategy for estimation of mycophenolic acid area under the concentration time curve in patients receiving concomitant sirolimus or cyclosporine.
    Figurski MJ; Nawrocki A; Pescovitz MD; Bouw R; Shaw LM
    Ther Drug Monit; 2008 Aug; 30(4):445-55. PubMed ID: 18641543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring mycophenolic acid pharmacokinetic parameters in liver transplant recipients: prediction of occurrence of leukopenia.
    Hao C; Anwei M; Bing C; Baiyong S; Weixia Z; Chuan S; Erzhen C; Xiaxing D; Weihua Q; Weiping Y; Chenghong P; Hongwei L
    Liver Transpl; 2008 Aug; 14(8):1165-73. PubMed ID: 18668650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation.
    Hale MD; Nicholls AJ; Bullingham RE; Hené R; Hoitsma A; Squifflet JP; Weimar W; Vanrenterghem Y; Van de Woude FJ; Verpooten GA
    Clin Pharmacol Ther; 1998 Dec; 64(6):672-83. PubMed ID: 9871432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of mycophenolic acid in senile Chinese kidney transplant recipients.
    Wang CX; Meng FH; Chen LZ; Ren B; Li SX; Fei JG; Qiu J; Deng SX; Li J; Chen SY
    Transplant Proc; 2007 Jun; 39(5):1392-5. PubMed ID: 17580146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.